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Dr. James Jett launched Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer (IASLC) in January 2006 and, 
with his editorial team, has guided this journal to be the worldwide premier journal focus-
ing on thoracic oncology. Dr. Jett stepped down as Editor-in-Chief on December 31, 2012, 
and I have the honor of taking over the helm of this illustrious journal on January 1, 2013.
For me, this is déjà vu, and evokes memories from years past. In 2005, after several 
years of working and learning under Dr. Jett on the lung committee of the North Central 
Cancer Treatment Group, I took over as the Chairman of the lung committee—incidentally, 
to free up his time to run JTO! Then and now, very few changes will be made as I build on 
the success of what my mentor, Dr. Jett, has created.
The changes we will make to the journal stems directly from our specific scope and 
mission, under the Instruction for Authors section of the journal:
JTO, the official journal of the IASLC, is the primary educational and informational 
publication for topics relevant to detection, prevention, diagnosis, and treatment of tho-
racic malignancies. JTO emphasizes a multidisciplinary approach and includes original 
research (clinical trials and translational or basic research), reviews, and opinion pieces. 
The audience consists of epidemiologists, medical oncologists, radiation oncologists, tho-
racic surgeons, pulmonary specialists, radiologists, pathologists, and research scientists 
with a special interest in thoracic oncology.
With the expanding success of the journal, the editorial board membership will be 
updated and aligned to meet the challenges of the future, by representation from specialties 
such as genomics, genetic epidemiology, quality of life, symptom control, survivorship, 
outcomes research, health economics, and public policy. With this alignment, new member-
ship to the editorial board will continue to represent the multidisciplinary nature of thoracic 
oncology as well as the large international membership of IASLC.
A challenging problem continues to be disparity between the amount of high quality 
scientific material to be published and the space constraints in the journal. As such, strict 
page limits will be imposed on all types of submissions. Authors submitting materials to 
the journal should refer to the instruction for authors section for these new more restrictive 
page limits. Other enhancements to content, subject matter, and guidelines to the nature and 
type of desired manuscripts will be forthcoming and clearly described when I introduce the 
revamped editorial board.
In closing, I want to thank Dr. James Jett for building a foundation and track record, 
which makes it easy and so interesting to expand on. I also want to thank the Board of 
Directors, Publication Committee, and the entire membership of IASLC for giving me the 
opportunity to grow this journal with them.
Of course, all suggestions for improvement of the journal are welcome. Please send 
me your contact information if you are interested in volunteering for membership on the 
editorial board or to join our rank of dedicated reviewers.
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